Correction: National Prevalence and Trends of HIV Transmitted Drug Resistance in Mexico
Santiago Ávila‐Ríos(Instituto Nacional de Enfermedades Respiratorias), Jaime Andrade‐Villanueva(Hospital Civil de Guadalajara), Daniela Garrido-Rodríguez(Instituto Nacional de Enfermedades Respiratorias), Gustavo Reyes‐Terán, Samuel Navarro-Álvarez(Oasis of Hope Hospital), Claudia García‐Morales(Instituto Nacional de Enfermedades Respiratorias), Christopher E. Ormsby(Instituto Nacional de Enfermedades Respiratorias), Ramón Hernández‐Juan(Instituto Nacional de Enfermedades Respiratorias), Luz Alicia González-Hernández(Universidad de Guadalajara), Indiana Torres-Escobar(Benemérita Universidad Autónoma de Puebla)
Cited by 0
Related Papers
Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season
|Proceedings of the National Academy of Sciences|2014|241
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
|The Lancet Respiratory Medicine|2021|225
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
|The Lancet Infectious Diseases|2011|172
Identification and characterization of HIV-specific resident memory CD8 <sup>+</sup> T cells in human lymphoid tissue
|Science Immunology|2018|170
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies
|Science Translational Medicine|2017|169